[SS7-5]
Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.
Presentation information
[CINP2024] Spotlight Session
CINP2024 » Spotlight Session
Spotlight Session 7
Pharmacology and therapeutics of psychedelics
GNC Mini-Symposium
Sat. May 25, 2024 2:30 PM - 3:30 PM Room 2 (Hall B7 (1))
Chair: Gabriella Gobbi (McGill University)
Abstract:
With this mini symposium, the CINP Psychedelic Pharmacology Global Network (GNC) aims at giving an overview of the state of the art of preclinical and clinical research on the therapeutics of psychedelics. We will offer basic knowledge to scientists who want to know more about the mechanism of action of psychedelics and their clinical application.
Dr. Gobbi will introduce the session explaining the goal of the symposium and the role of the CINP Psychedelic Pharmacology GNC in the present and future.
Then, Dr. De Gregorio will give an overview on the historical classification of psychedelics and hallucinogenic compounds and the need for a more comprehensive modern classification.
Dr. Tani will focus on the description of clinical evidence of psychedelics. He will demonstrate the clinical and neuroimaging findings from their double-blind, randomized, placebo-controlled trial of intravenous ketamine infusion in patients with treatment-resistant depression (TRD). Then, the clinical evidence on the therapeutic benefits and adverse effects of psychedelics, especially the use of psilocybin for depression, will be reviewed. Furthermore, he will present their upcoming clinical trial of psilocybin in Japan in patients with TRD.
Dr. Musazzi will give an overview of mechanistic studies in preclinical models aimed at trying to elucidate the cellular mechanisms underlying the pharmacological properties of psychedelics. Indeed, preclinical studies have much to offer psychedelic research as they allow a tight control of experimental parameters and the possibility of elucidating the relevant signaling cascades that mediate therapeutic outcome. Nevertheless, the mechanisms involved in the effects of psychedelics are still far to be fully elucidated.
Finally, Dr. Gobbi and Dr. Martinotti will lead a round table discussion involving basic researchers and clinicians. The session will include a question-and-answer segment from the audience, focusing on the deepening of key features and concerns regarding the use of psychedelics as therapeutic drugs.
Overall, the mini symposium aims to provide fundamental information on the current status of psychedelics and to foster an open dialogue on psychedelic research between clinicians and preclinical scientists. This initiative seeks to promote the translational approach necessary for gaining further insights into the mechanisms of rapid psychotropic effects and for advancing psychedelics toward clinical practice.